Evogene Annual Meeting Adjourned Due to Lack of Quorum
Ticker: EVGN · Form: 6-K · Filed: Jun 6, 2024 · CIK: 1574565
Sentiment: neutral
Topics: meeting-adjournment, corporate-governance, shareholder-meeting
TL;DR
Evogene's shareholder meeting postponed a week due to no-shows, reconvening June 13th.
AI Summary
Evogene Ltd. held its Annual General Meeting of Shareholders on June 6, 2024, but it was adjourned for one week due to a lack of quorum. The meeting will now reconvene on June 13, 2024, at 3:00 p.m. at the same location.
Why It Matters
The adjournment of the annual meeting could indicate shareholder engagement issues or a lack of consensus on key proposals, potentially impacting corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is a procedural update regarding a meeting adjournment and does not contain material financial or operational news.
Key Players & Entities
- Evogene Ltd. (company) — The company holding the Annual General Meeting.
- June 6, 2024 (date) — Date of the originally scheduled Annual General Meeting.
- June 13, 2024 (date) — Date the Annual General Meeting is rescheduled to.
FAQ
Why was the Annual General Meeting of Shareholders adjourned?
The meeting was adjourned due to a lack of quorum.
When will the Evogene Ltd. Annual General Meeting reconvene?
The meeting will reconvene on Thursday, June 13, 2024.
What time is the reconvened Annual General Meeting?
The meeting will be held at 3:00 p.m.
Where will the reconvened Annual General Meeting take place?
The meeting will be held at the same place as originally scheduled.
What is the filing type and date?
This is a Form 6-K filed on June 6, 2024.
Filing Stats: 282 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2024-06-06 16:02:44
Filing Documents
- zk2431559.htm (6-K) — 8KB
- 0001178913-24-001950.txt ( ) — 9KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On June 6, 2024, Evogene Ltd. (the " Company ") convened its Annual General Meeting of Shareholders (the " Annual Meeting "), however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company's Annual Meeting will be reconvened on Thursday, June 13, 2024 at 3:00 p.m. (Israel time), at the executive offices of the Company, 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel. The contents of Exhibit 99.1 to this Form 6-K are incorporated by reference into the registration statements on Form F-3 (File No. 333-277565 ) and on Form S-8 (File Nos. 333-193788 , 333-201443 , 333-203856 and 333-259215 ) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 6, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer